Related Experiment Video
Updated: Jun 26, 2025
Isolation of Endothelial Progenitor Cells from Human Umbilical Cord Blood
Published on: September 14, 2017
Endothelial progenitor cells for diabetic cardiac and kidney disease
Matthew J Raleigh1,2, Sachin V Pasricha3, Aaron Nauth2
1Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Unity Health, Toronto, Ontario M5B 1T8, Canada.
Insights
Diabetic cardiac and kidney disease share common pathology, often driven by endothelial dysfunction. Endothelial progenitor cell therapy shows promise for treating these conditions, with novel approaches enhancing its effectiveness.
Area of Science:
- Cardiovascular Medicine
- Nephrology
- Endocrinology
Background:
- Diabetes mellitus management is a global health challenge.
- Diabetic cardiac and kidney diseases frequently co-occur, worsening patient prognosis.
- A shared underlying pathology likely links these diabetic end-organ complications.
Purpose of the Study:
- To elucidate the mechanistic link between diabetic cardiac and kidney disease.
- To highlight the role of endothelial dysfunction in both conditions.
- To explore the potential of cellular therapy, specifically endothelial progenitor cells, for treating cardio-renal complications.
Main Methods:
- Review of preclinical and clinical evidence for endothelial progenitor cell therapy.
- Examination of endothelial dysfunction as a common pathway.
- Discussion of novel therapeutic strategies including cell enhancement and extracellular vesicles.
Main Results:
- Endothelial dysfunction is identified as a key mechanistic link between diabetic cardiac and kidney disease.
- Preclinical and clinical studies support the efficacy of endothelial progenitor cell therapy in cardiac, kidney, and cardio-renal models.
- Emerging approaches like cell enhancement and extracellular vesicles offer potential improvements.
Conclusions:
- Endothelial progenitor cell therapy represents a promising strategy for managing diabetic cardio-renal complications.
- Further research into cell enhancement and extracellular vesicles could optimize therapeutic outcomes.
- Addressing endothelial dysfunction is crucial for mitigating diabetic end-organ damage.
Abstract:
The management of diabetes mellitus and its resultant end organ dysfunction represents a major challenge to global health-care systems. Diabetic cardiac and kidney disease commonly co-occur and are significant contributors to the morbidity and mortality of patients with diabetes, carrying a poor prognosis. The tight link of these parallel end organ manifestations suggests a deeper common underlying pathology. Here, we outline the mechanistic link between diabetic cardiac and kidney disease, providing evidence for the role of endothelial dysfunction in both processes and the potential for cellular therapy to correct these disorders. Specifically, we review the preclinical and clinical evidence for endothelial progenitor cell therapy in cardiac, kidney, and cardio-renal disease applications. Finally, we outline novel approaches to endothelial progenitor cell therapy through cell enhancement and the use of extracellular vesicles, discussing published and future work.
More Related Videos
08:43Isolation of Endothelial Progenitor Cells from Healthy Volunteers and Their Migratory Potential Influenced by Serum Samples After Cardiac Surgery
Published on: February 14, 2017
13:46Phenotypic and Functional Characterization of Endothelial Colony Forming Cells Derived from Human Umbilical Cord Blood
Published on: April 13, 2012
